GeneDx (NASDAQ:WGS), trading on NASDAQ under the symbol WGS, is a leading provider of high‐quality genetic testing services with a focus on rare and ultra‐rare inherited conditions. Since its founding in 2000, the company has pioneered the use of whole exome sequencing, chromosomal microarrays and targeted gene panels to deliver comprehensive diagnostic insights. GeneDx’s laboratory in Gaithersburg, Maryland, is CLIA‐certified and CAP‐accredited, reflecting its commitment to rigorous quality standards and clinical utility.
The firm’s core offerings span a broad range of clinical specialties, including neurology, cardiology, oncology, immunology and pediatric medicine. GeneDx’s rare disease testing service utilizes advanced next‐generation sequencing technologies to analyze thousands of genes simultaneously, supporting earlier and more accurate diagnoses. In addition to diagnostic tests, the company provides pharmacogenomic screening, reproductive carrier screening and noninvasive prenatal screening, enabling physicians and patients to make informed treatment and family planning decisions.
GeneDx serves a global clientele, partnering with clinicians, hospitals and academic centers in the United States, Europe, Asia and beyond. Through collaborative relationships with specialty laboratories and research institutions, the company extends its testing capabilities to more than 90 countries. Over the years, GeneDx has expanded its international footprint via strategic alliances and participation in multi‐center research initiatives, reinforcing its reputation as a trusted partner in precision medicine and translational genomics.
The company is guided by a leadership team of seasoned experts in molecular diagnostics, clinical laboratory operations and health care strategy. Leveraging decades of combined experience, the executive management continues to drive innovation in genomic medicine while maintaining operational excellence. As part of the BioReference Laboratories family, GeneDx benefits from shared resources in regulatory compliance, information technology and business development, positioning it for sustained growth in the rapidly evolving field of genetic testing.
